Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate

British Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2007, Pages 698-705

  Tayab, Zia R ^a   Fardon, Tom C ^b   Lee, Daniel K C ^b   Haggart, Kay ^b   McFarlane, Lesley C ^b   Lipworth, Brian J ^b   Hochhaus, Günther ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Fluticasone propionate; Mometasone furoate; Plasma protein binding; Pulmonary deposition; Systemic side effects

Indexed keywords

CREATINE; FLUTICASONE PROPIONATE; HYDROCORTISONE; MOMETASONE FUROATE; MONTELUKAST; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; HYDROCORTISONE URINE LEVEL; IC 50; INHALER; MALE; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RECEPTOR BINDING; STATISTICAL SIGNIFICANCE; STEADY STATE; ULTRACENTRIFUGATION;

ADMINISTRATION, INHALATION; ADULT; AGED; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PREGNADIENEDIOLS; PROTEIN BINDING; TREATMENT OUTCOME;

EID: 35248838260     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02919.x     Document Type: Article

References (36)

1. WHO. WHO fact sheet no. 206. Geneva : World Health Organization 2005.
2. Barnes PJ, Adcock IM. Steroid resistance in asthma. QJM 1995 88 : 455 68.
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998 157 (3, Part 2 S1 53.
4. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997 52 (39 Suppl. 1 34.
5. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary- adrenal axis function. Thorax 1993 48 : 233 8.
6. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 1999 159 : 941 55.
7. Mak VH, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Respir J 1992 5 : 1068 74.
8. Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001 23 : 1339 54.
9. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998 101 (4, Part 2 S440 6.
10. Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004 170 : 960 6.
11. Rago RP, Einstein A Jr., Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2003 51 : 297 305.
12. Onrustand SV, Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998 56 : 725 45.
13. Storms WW. Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: review of comparator studies. Allergy 1995 50 (23 Suppl. 25 9.
14. Issar M, Sahasranaman S, Buchwald P, Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Resp J 2006 27 : 511 6.
15. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001 61 : 1325 50.
16. Affrime MB, Cuss F, Padhi D, Wirth M, Pai S, Clement RP, Lim J, Kantesaria B, Alton K, Cayen MN. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000 40 : 1227 36.
17. Mackie AE, McDowall JE, Falcoz C, Ventresca P, Bye A, Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Clin Pharmacokinet 2000 39 (Suppl. 1 23 30.
18. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler (R) Is twice that from a pressurized metered-dose inhaler P-Mdi. Eur Resp J 1994 7 : 1839 44.
19. Schering-Plough. Mometasone furoate package insert. Kenilwoth, NJ : ScheringPlough 2004.
20. GlaxoSmithKline. Fluticasone propionate package insert. Brentford : GlaxoSmithKline 2004.
21. Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Mollmann H, Derendorf H. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996 36 : 938 41.
22. Rohatagi S, Krishnaswami S, Pfister M, Sahasranaman S. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. Am J Ther 2005 12 : 385 97.
23. Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab Dispos 2006 34 : 225 33.
24. Beal SL, Boeckman A, Sheiner LB. NONMEM Users' Guides, version IV. San Francisco : NONMEM Project Group, University of California 1992.
25. Issar M, Sahasranaman S, Buchwald P, Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J 2006 27 : 511 6.
26. Ryrfeldt A, Andersson P, Edsbaecker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982 63 (Suppl. 122 86 95.
27. Hochhaus G, Mollmann H, Derendorf H, Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997 37 : 881 92.
28. Edsbacker S, Johansson CJ. Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Toxicol 2006 98 : 523 36.
29. Derendorf H, Daley-Yates PT, Pierre LN, Efthimiou J. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J Clin Pharmacol 2002 42 : 383 7.
30. Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, Woodcock A. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000 356 : 556 61.
31. Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, Hochhaus G, Tattersfield AE. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol 2006 62 : 412 9.
32. Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K. Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol 1993 44 : 141 5.
33. Derendorf H, Hochhaus G, Mollmann H, Barth J, Krieg M, Tunn S, Mollmann C. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol 1993 33 : 115 23.
34. Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C, Huang Y, Chen K, David M, Nave R, King SP. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005 12 : 201 9.
35. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 1999 75 : 274.
36. Taylor S, Harker A. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal 2006 41 : 299 303.